In Vivo Pharmacological Effects of Ciclosporin and Some Analogues

Borel, J. F.; Baumann, Götz; Chapman, Ian; Donatsch, P.; Fahr, Alfred; Mueller, Edgar A.; Vigouret, J. M.

doi:10.1016/s1054-3589(08)60276-8

Cited by 129 publications

(136 citation statements)

References 510 publications

Supporting

Mentioning

135

Contrasting

Order By: Relevance

“…Its efficacy in controlling ocular inflammation has been previously demonstrated (5). It blocks helper T-lymphocyte proliferation and IL-2 production (7)(8). Moreover Cyc inhibits histamine release from human mast cells and basophils and it may also reduce eosinophil recruitment in the conjunctiva through the inhibition ofIL-5 production.…”

mentioning

confidence: 99%

Long-Term Safety and Efficacy of Topical Cyclosporine in 156 Children with Vernal Keratoconjunctivitis

Pucci

Caputo

Mori³

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Vernal keratoconjunctivitis (VKC) is a chronic and potentially sight-threatening disease. Topical corticosteroids (Cs) seem to be the only effective treatment for this condition, although severe side effects may occur owing to their prolonged use. More recently, cyclosporine (Cyc) eye drops have been reported as a valid alternative, but so far such treatment has only been successfully experimented for a short time and in small numbers of patients. The aim of our study is to evaluate the long term safety and efficacy of topical cyclosporine eye drops in children suffering from VKC. Over a period of 7 years we followed a large group of children suffering from severe VKC. They were selected to start cyclosporine eye drop treatment, because of the prompt relapse of their disease as soon as they stopped topical corticosteroids administration. All patients were followed-up in an ambulatory care assessment. A total of 156 children with VKC were treated with topical cyclosporine eye drops over a period ranging from two to seven years (mean time 3.8±1.09 years) during the seasonal relapse (range 9-66 months; mean time 24.7±10.4 months). Two formulations, at 1% and 2% (82% and 18% respectively) concentrations, of cyclosporine eye drops were made. The dosage administered was one drop in each eye from two to four times a day, depending on the severity of the disease and the season. The ocular objective scores were determined and compared every year, at the beginning and at the end of each treatment period. Blood samples were collected once a year in order to check both kidney and liver functions, as well as cyclosporine serum levels. We enrolled 156 patients (mean age 8.31±2.79 years; 116 males and 40 females) who were followed-up over a period of 7 years (156 (100%) children during the first and the second year; 138 (88.5%) patients until the third year; 90 (57.7%) until the fourth year; 32 (20.5%) until the fifth year; 10 (6.4%) until the sixth year and 2 (1.3%) until the seventh year). The ocular objective scores significantly improved (p<.OOI) over the years when comparing them at the beginning and the end of each seasonal treatment period, except for the last year. Over the treatment period, non-significant changes were recorded in terms of kidney and liver enzymatic activities and also in terms of cyclosporine serum levels. Cyclosporine eye drops, either at 1% or 2% concentrations, resulted safe and effective for long-term treatment of VKC in 156 children. The lack of significance of the score results during the seventh year can be explained by the small number of subjects treated for such a long period. A systematic ocular examination and both liver and kidney functional investigations allowed us to exclude the possibility of local or systemic side effects due to cyclosporine. If either transient or long-lasting, the occurrence of burning was referred by some of the patients treated, but none of them required to discontinue the drug. In conclusion, this is the first study showing that topical cyclosporine is easily h...

show abstract

mentioning

confidence: 99%

Long-Term Safety and Efficacy of Topical Cyclosporine in 156 Children with Vernal Keratoconjunctivitis

Pucci

Caputo

Mori³

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…The immunosuppressive activity of CsA is generally attributed to the inhibition of the protein phosphatase calcineurin, mediated by the complex of cyclophilin A (CypA) and CsA (Borel et al, 1996). The binding domains for CypA and calcineurin are located at different sites on the cyclosporin molecule (Fig.…”

Section: Discussionmentioning

confidence: 99%

Perioperative Neuroprotection Symposium

Fiskum¹

2004

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour par the data needed, and completing and reviewing this collection of information. Send conranls reducing this burden to Washington Headquarters Services. Directorate for Information Operations Management and Budget, Paperwork Reduction Protect (0704-01681. Washington, DC 20803Indudkig the «ma for reviewing instructions, searching existing data sources, gathering and maintaining tMs burden estimate or any other aspect of this ooHecMon of information, including suggestions for 1218 Jefferson Davis Highway, Suite 1204, Arttngton, VA 22202-4302, and to the Office of AGENCY USE ONLY (Leave blank) REPORT DATE June 2004 REPORT TYPE AND DATES COVERED Final Proceedings (13 Sep 03-22 May 04) TITLE AND SUBTITLE Perioperative Neuroprotection Symposium AUTHOR(S)Gary Fiskum, Ph.D. S. FUNDING NUMBERS DAMD17-03-1-0500 PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)University of Maryland, Baltimore Baltimore, MD 21201 E-Mail: gfisk001@umaryland.edu PERFORMING ORGANIZATION REPORT NUMBER SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 SPONSORING / MONITORING AGENCY REPORT NUMBER SUPPLEMENTARY NOTESOriginal contains color plates: ALL DTIC reproductions will be in black and white 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE A-TRACT IMaiiliwyiH 200 VVwW)The Perioperative Neuroprotection Symposium was held on April 16-19 in Ft. Lauderdale, Fl. The meeting was attended by approximately 140 registrant». Twenty four invited speakers made presentations in five sessions. An additional 40 poster presentations were^available for discussion throughout the meeting. Each participant received a symposium abstract book that included mini-reviews from each of the speakers and the short abstracts from the posters. The speakers also submitted formal manuscripts for peer-reviewed publication.Five of the poster presenters were also invited to submit short research manuscripts. Mitochondria and Neuroprotection Symposium April [16][17][18][19] 2004 Albert Lester Lehninger February 17,1917-March4,1986 Albert Lehninger was born in Bridgeport, Connecticut and received a B.A. in English from Wesleyan University in 1939. He received his Ph.D. in Physiological Chemistry from the University of Wisconsin in 1942. Lehninger stayed on at the Univ. of Wisconsin as an Instructor until 1945, when he was appointed Assistant Professor of Biochemistry and Surgery at the University of Chicago. At this juncture he had published 11 research articles. From 1945From -1952, he published an additional 33 articles. These studies included the discovery that fatty acid oxidation, ketone body metabolism, and the TCA cycle occur in the mitochondrion, some of the first investigations employing isolation of this organelle (see e.g., JBC1949 and 1950). Thus, while Lehninger was a chemist at heart, he was one of the founding father...

show abstract

“…[33] The 1-year survival rate following liver transplantation was 30% to 50% prior to the discovery of cyclosporine-A, [34,35] however, after the introduction of cyclosporine-A, the 1-year and 3-year survival rates were 74% and 67% in the first 1000 recipients treated with cyclosporine-A at the University of Pittsburgh in the early 1980s. [36] After these good results, growth of liver transplantation was facilitated by the conclusion of the National Institute of Health Consensus Development Conference in 1983 that liver transplantation is not an experimental procedure but an effective therapy that deserves broader application.…”

Section: Evolution Of Immunosuppressionmentioning

confidence: 99%

History and Evolution of Liver Transplantation

Azzam¹

2012

Liver Transplantation - Basic Issues

View full text Add to dashboard Cite

In Vivo Pharmacological Effects of Ciclosporin and Some Analogues

Cited by 129 publications

References 510 publications

Long-Term Safety and Efficacy of Topical Cyclosporine in 156 Children with Vernal Keratoconjunctivitis

Long-Term Safety and Efficacy of Topical Cyclosporine in 156 Children with Vernal Keratoconjunctivitis

Perioperative Neuroprotection Symposium

History and Evolution of Liver Transplantation

Contact Info

Product

Resources

About